Prediction of drug–ABC-transporter interaction — Recent advances and future challenges☆
暂无分享,去创建一个
[1] G. Ecker,et al. Predicting Ligand Interactions with ABC Transporters in ADME , 2009, Chemistry & biodiversity.
[2] Peter W Swaan,et al. Computational approaches to modeling drug transporters. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[3] K. Yoshioka,et al. Mutational analysis of the MRP2 gene and long-term follow-up of Dubin-Johnson syndrome in Japan , 2005, Journal of Gastroenterology.
[4] S. Chong,et al. P-gp Inhibition Potential in Cell-Based Models: Which “Calculation” Method is the Most Accurate? , 2008, The AAPS Journal.
[5] Gerhard F. Ecker,et al. Computational models for prediction of interactions with ABC-transporters. , 2008, Drug discovery today.
[6] F. Sharom,et al. Lipid bilayer properties control membrane partitioning, binding, and transport of p-glycoprotein substrates. , 2013, Biochemistry.
[8] R. Béliveau,et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. , 2002, Vascular pharmacology.
[9] P. Bungay,et al. Minimizing Drug Exposure in the CNS while Maintaining Good Oral Absorption. , 2012, ACS medicinal chemistry letters.
[10] Gerhard F. Ecker,et al. Exhaustive Sampling of Docking Poses Reveals Binding Hypotheses for Propafenone Type Inhibitors of P-Glycoprotein , 2011, PLoS Comput. Biol..
[11] A. di Pietro,et al. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[12] R. Callaghan,et al. How can we best use structural information on P-glycoprotein to design inhibitors? , 2007, Pharmacology & therapeutics.
[13] Stephen G Aller,et al. Refined structures of mouse P-glycoprotein , 2013, Protein science : a publication of the Protein Society.
[14] Peter W Swaan,et al. Identification of novel breast cancer resistance protein (BCRP) inhibitors by virtual screening. , 2013, Molecular pharmaceutics.
[15] Giuseppe Trapani,et al. New strategies to deliver anticancer drugs to brain tumors , 2009, Expert opinion on drug delivery.
[16] A. Kaddoumi,et al. Role of ABC transporters in the pathogenesis of Alzheimer's disease. , 2012, ACS chemical neuroscience.
[17] Dan Li,et al. ADMET evaluation in drug discovery. 13. Development of in silico prediction models for P-glycoprotein substrates. , 2014, Molecular pharmaceutics.
[18] M. Jamei,et al. Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria , 2013, Drug Metabolism and Disposition.
[19] Teruaki Okuda,et al. Clarification of P-glycoprotein inhibition-related drug–drug interaction risks based on a literature search of the clinical information , 2014, Xenobiotica; the fate of foreign compounds in biological systems.
[20] G J Williams,et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1978, Archives of biochemistry and biophysics.
[21] Stephen A. Wring,et al. Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.
[22] S. Paine,et al. Can long range mechanical interaction between drugs and membrane proteins define the notion of molecular promiscuity? Application to P-glycoprotein-mediated multidrug resistance (MDR). , 2013, Biochimica et biophysica acta.
[23] Jue Chen,et al. Crystal structure of the multidrug transporter P-glycoprotein from C. elegans , 2012, Nature.
[24] M. Hohl,et al. Crystal structure of a heterodimeric ABC transporter in its inward-facing conformation , 2012, Nature Structural &Molecular Biology.
[25] J. G. Kenna,et al. In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans , 2012, Drug Metabolism and Disposition.
[26] Gerhard F. Ecker,et al. Studies on propafenone-type modulators of multidrug resistance VI. Synthesis and pharmacological activity of compounds with varied spacer length between the central aromatic ring and the nitrogen atom , 1998 .
[27] M. X. Fernandes,et al. New Uses for Old Drugs: Pharmacophore‐Based Screening for the Discovery of P‐Glycoprotein Inhibitors , 2011, Chemical biology & drug design.
[28] Tingjun Hou,et al. ADME evaluation in drug discovery , 2002, Journal of molecular modeling.
[29] Lei Chen,et al. ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques. , 2011, Molecular pharmaceutics.
[30] H K Kroemer,et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.
[31] Ricardo J. Ferreira,et al. Insights on P-Glycoprotein's Efflux Mechanism Obtained by Molecular Dynamics Simulations. , 2012, Journal of chemical theory and computation.
[32] Christel A. S. Bergström,et al. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). , 2008, Journal of medicinal chemistry.
[33] A. Harris,et al. Reversal of multidrug resistance by verapamil and modulation by alpha 1-acid glycoprotein in wild-type and multidrug-resistant Chinese hamster ovary cell lines. , 1990, Cancer research.
[34] Zsolt Bikádi,et al. Predicting substrates of the human breast cancer resistance protein using a support vector machine method , 2013, BMC Bioinformatics.
[35] John N Weinstein,et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. , 2004, Cancer cell.
[36] T. Davis,et al. P-glycoprotein Modulates Morphine Uptake into the CNS: A Role for the Non-steroidal Anti-inflammatory Drug Diclofenac , 2014, PloS one.
[37] D. K. Williams,et al. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. , 2008, Molecular nutrition & food research.
[38] F. Russel,et al. In silico identification and in vitro validation of potential cholestatic compounds through 3D ligand-based pharmacophore modeling of BSEP inhibitors. , 2014, Chemical research in toxicology.
[39] Yue Weng,et al. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.
[40] Tudor I. Oprea,et al. A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. , 2011, Journal of medicinal chemistry.
[41] Gerhard F. Ecker,et al. Ligand and Structure-Based Classification Models for Prediction of P-Glycoprotein Inhibitors , 2013, J. Chem. Inf. Model..
[42] Yan Li,et al. Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2). , 2013, Food chemistry.
[43] Leslie Z. Benet,et al. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.
[44] Ricardo J. Ferreira,et al. Molecular Docking Characterizes Substrate-Binding Sites and Efflux Modulation Mechanisms within P-Glycoprotein , 2013, J. Chem. Inf. Model..
[45] K. Locher,et al. Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP‐PNP , 2007, FEBS letters.
[46] C. Scharinger,et al. A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities , 2014, European Neuropsychopharmacology.
[47] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[48] Andreas Bender,et al. P-glycoprotein Substrate Models Using Support Vector Machines Based on a Comprehensive Data set , 2011, J. Chem. Inf. Model..
[49] G. Ecker,et al. Structure–Activity Relationships, Ligand Efficiency, and Lipophilic Efficiency Profiles of Benzophenone-Type Inhibitors of the Multidrug Transporter P-Glycoprotein , 2012, Journal of medicinal chemistry.
[50] Ricardo J. Ferreira,et al. Toward a Better Pharmacophore Description of P-Glycoprotein Modulators, Based on Macrocyclic Diterpenes from Euphorbia Species , 2011, J. Chem. Inf. Model..
[51] A. Barr,et al. Structures of ABCB10, a human ATP-binding cassette transporter in apo- and nucleotide-bound states , 2013, Proceedings of the National Academy of Sciences.
[52] Floriane Montanari,et al. BCRP Inhibition: from Data Collection to Ligand‐Based Modeling , 2014, Molecular informatics.
[53] Katrin Wlcek,et al. ATP‐binding cassette transporters in liver , 2014, BioFactors.
[54] Hassane S. Mchaourab,et al. On the Origin of Large Flexibility of P-glycoprotein in the Inward-facing State* , 2013, The Journal of Biological Chemistry.
[55] E. Pardon,et al. Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain , 2013, Proceedings of the National Academy of Sciences.
[56] Peter A. Edwards,et al. Role of ABC transporters in lipid transport and human disease , 2013, Trends in Endocrinology & Metabolism.
[57] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[58] Chris T. A. Evelo,et al. Applying linked data approaches to pharmacology: Architectural decisions and implementation , 2014, Semantic Web.
[59] G R Wilkinson,et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[60] Louis-David Cantin,et al. Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs: Opportunities Provided by Physicochemical Property Modulation, In Silico Modeling, and Structural Modification , 2012, Drug Metabolism and Disposition.
[61] D. Duś,et al. 8-Prenylnaringenin is an inhibitor of multidrug resistance-associated transporters, P-glycoprotein and MRP1. , 2010, European journal of pharmacology.
[62] Gerhard F Ecker,et al. An In Silico Classification Model for Putative ABCC2 Substrates , 2012, Molecular informatics.
[63] N. Shaik,et al. Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design , 2009, Drug Metabolism and Disposition.
[64] R. Dawson,et al. Structure of a bacterial multidrug ABC transporter , 2006, Nature.
[65] M. Trauner,et al. The Role of Canalicular ABC Transporters in Cholestasis , 2014, Drug Metabolism and Disposition.
[66] A. di Pietro,et al. C-Isoprenylation of flavonoids enhances binding affinity toward P-glycoprotein and modulation of cancer cell chemoresistance. , 2001, Journal of medicinal chemistry.
[67] N. Shinomiya,et al. ABCG2/BCRP Dysfunction as a Major Cause of Gout , 2011, Nucleosides, nucleotides & nucleic acids.
[68] Lei Chen,et al. Computational models for predicting substrates or inhibitors of P-glycoprotein. , 2012, Drug discovery today.
[69] J. Dodge,et al. Structure/activity relationships , 1998 .
[70] T. Ranheim,et al. Tangier disease caused by compound heterozygosity for ABCA1 mutations R282X and Y1532C. , 2010, Atherosclerosis.
[71] Sean Ekins,et al. Pharmacophore-based discovery of ligands for drug transporters. , 2006, Advanced drug delivery reviews.
[72] J. Beijnen,et al. Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699) , 2014, Pharmaceutical Research.
[73] Hui Zhang,et al. Support vector machine and pharmacophore-based prediction models of multidrug-resistance protein 2 (MRP2) inhibitors. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[74] Evan Bolton,et al. PubChem's BioAssay Database , 2011, Nucleic Acids Res..
[75] K. Linton,et al. AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Molecular Mechanistic Explanation for the Spectrum of Cholestatic Disease Caused by the S320F Variant of ABCB4 , 2014 .
[76] Matthew P. Jacobson,et al. Predicting Binding to P-Glycoprotein by Flexible Receptor Docking , 2011, PLoS Comput. Biol..
[77] A. Tropsha,et al. Human Intestinal Transporter Database: QSAR Modeling and Virtual Profiling of Drug Uptake, Efflux and Interactions , 2013, Pharmaceutical Research.
[78] R. Stroud,et al. Subnanometre-resolution electron cryomicroscopy structure of a heterodimeric ABC exporter , 2014, Nature.
[79] S-M Huang,et al. Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence‐Based Position , 2013, Clinical pharmacology and therapeutics.
[80] Marilyn E. Morris,et al. Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2) , 2009, The AAPS Journal.
[81] J. Beijnen,et al. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387. , 2013, Pharmacological research.
[82] Ulf Norinder,et al. Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs , 2009, Pharmaceutical Research.
[83] W. Dalton,et al. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. , 1991, Blood.
[84] Paola Vergani,et al. The ABC protein turned chloride channel whose failure causes cystic fibrosis , 2006, Nature.
[85] Barbara Zdrazil,et al. Annotating Human P-Glycoprotein Bioassay Data , 2012, Molecular informatics.
[86] Vasilis Vasiliou,et al. Human ATP-binding cassette (ABC) transporter family , 2009, Human Genomics.
[87] Geoffrey Chang,et al. Flexibility in the ABC transporter MsbA: Alternating access with a twist , 2007, Proceedings of the National Academy of Sciences.